Nitazoxanide is in clinical development for the treatment of the common cold due to rhinovirus or other forms of enterovirus infection in adults and children aged 12 years and older. The common cold occurs amongst all population groups and most people will experience multiple infections a year. Currently, there are no treatment options approved to treat the common cold and most recommended management strategies are ineffective at relieving the associated symptoms.
Nitazoxanide for treatment of common cold due to rhinovirus or other enterovirus infection
Nitazoxanide is in clinical development for the treatment of the common cold due to rhinovirus or other forms of enterovirus infection in adults and children aged 12 years and older.
Interventions:
Nitazoxanide (NT-300; NTZ; PH-5776)
Indications:
Common cold
Therapeutic Areas:
Infectious Disease
Year:
2021